By effectively combining trastuzumab’s targeted binding of human epidermal growth factor receptor 2 (HER2) with the potent cytotoxic agent DM1, ado-trastuzumab emtansine (T-DM1) enables selective cancer cell killing while reducing systemic toxicity and side effects. Here, ERBB2 is linked to cancer.